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CARTA AO EDITOR
day of treatment patients are taught about the proce-
dure, the care that has to be taken with the catheter and
infusion device and the warning signs that should make
the patient to promptly look for medical care.
The preparation of the drug in an elastomeric pump
is carried out with an aseptic technique, by diluting
250 micrograms of iloprost in 237,5 mL of saline. After -
wards the pump is connected to a peripheral catheter,
which should be placed in a medium-sized vein, ideal-
ly in the forearm; tortuous vessels and veins located in
areas where the catheter can be easily bended should
be avoided. The pump must be carried in a pouch
around the patients’ neck so that it is higher than the
venous access, to avoid perfusion problems.
The treatment is kept for 5 consecutive days, during
which the healthcare team, including the specialist
nurse, is easily reachable by phone. At the 5th day of
treatment the patient can either attend our day-hospi-
tal unit or his primary care centre to remove the pe-
ripheral access.
The treatment was generally very well tolerated,
without any patient reporting nausea, headache, or hy-
potension. One patient who did not tolerate iloprost
perfusion, tolerated it through elastomeric pump. Dif-
ficulty in keeping the peripheral catheter was reported
by one patient with limited cutaneous SSc during the
first infusion, but improved in the following adminis-
trations. In 4 of the 25 infusions there was still a small
amount of iloprost left in the pump at the last day of
treatment, although this did not seem to compromise
the efficacy.
All patients clinically improved, with reduction of
digital pain associated with ischaemia and healing of
DU (including ulcers with evidence of critical is-
chaemia). 
Iloprost domiciliary infusion through elastomeric
pump is safe, effective and easily handled by patients,
who can remain at home and keep their daily activi-1. Rheumatology, Hospital Garcia de Orta, Almada, Portugal.
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Dear Editor,
Vasculopathy is crucial in the pathogenesis of seve -
ral systemic rheumatic diseases, with Raynaud’s pheno -
menon (RP) and digital ulcers (DU) being the clinical
manifestations that best illustrate it.
European League Against Rheumatism recommends
the use of intravenous iloprost for the treatment of sys-
temic sclerosis (SSc) related digital vasculopathy, as it
reduces the frequency and severity of SSc-RP attacks
and heals active DU1.
The standard treatment protocol consists of intra-
venous infusion of iloprost at a rate of 0.5–2 ng/kg/min
for 3–5 consecutive days, through a peripheral venous
access. Due to common side effects (hypotension,
flushing, nausea and headaches) patients used to be ad-
mitted into hospital for treatment administration. How-
ever, this has an important economic impact, not only
due to the direct costs of hospitalisation, but also for the
“price” of absenteeism.
Portable devices for iloprost infusion have been re-
cently designed, allowing outpatient treatment. The
drug is kept in an elastomeric pump that does not
change the physical-chemical properties and enables a
constant and continuous release of iloprost2. The device
has demonstrated to be safe, feasible and effective3–6,
with higher patients’ satisfaction and consequently
greater treatment adherence4.
Since 2015, 12 patients followed in our rheumatol-
ogy department have received intravenous iloprost
treatment on an outpatient basis, with a total of 25 in-
fusions. The underlying connective tissue disease, the
concomitant vasodilator therapies and the number of
infusions per patient are described in Table I. 
All patients admitted at our day-hospital unit for ilo-
prost infusion are previously evaluated by a clinician,
who decides the eligibility for this treatment. In the first
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ties. Our data reinforce the feasibility of iloprost treat-
ment administration in home care and this approach
could be implemented in other centres as a first-choice
for iloprost intravenous infusion. 
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TABLE I. SummAry InformATIon of pATIEnTS TrEATEd wITh domIcILIAry InTrAvEnouS ILoproST 
Gender Age (years) Connective tissue disease Concomitant therapies Infusions
Female 53 MCTD nifedipine, transdermal isosorbide 6
mononitrate, sildenafil
Female 62 Limited cutaneous SSc nifedipine, transdermal isosorbide mononitrate 1
Female 70 Limited cutaneous SSc nifedipine, transdermal isosorbide mononitrate, 4
bosentan, sildenafil
Female 77 Limited cutaneous SSc nifedipine 1
Female 56 Limited cutaneous SSc nifedipine, bosentan 2
Female 56 Diffuse cutaneous SSc nifedipine 2
Female 67 (†) Diffuse cutaneous SSc amlodipine, bosentan 1
Female 44 Diffuse cutaneous SSc nifedipine, transdermal isosorbide 
mononitrate, bosentan 1
Female 40 SSc overlap myositis nifedipine 2
Female 42 Buerger’s disease nifedipine 2
Male 36 MCTD nifedipine 1
Male 80 Limited cutaneous SSc nifedipine 2
MCTD: mixed connective tissue disease; SSc: systemic sclerosis
